A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1
112
about 6 years
18+
6 sites in FL, OH, TN +1
What this study is about
Researchers are testing a treatment called BTX-A51 to see if it's safe, how well it works, and what the best dose might be. The trial will involve people with advanced solid tumors or breast cancer. It will happen in three phases: Phase 1a to find the right dose, Phase 1b to see if it works alone, and Phase 1c to test it when combined with another medication.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BTX-A51
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Defining the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of BTX-A51alone and in combination with fulvestrant, Incidence of adverse events after BTX-A51 administration alone and in combination with fulvestrant
Secondary: Duration of response (DoR), Half-life of BTX-A51, Objective response rate (ORR), Overall survival (OS), Progression free survival (PFS)
Oncology